Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme
Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme
复制标题
DOI：
10.1097/00006231-200104000-00003
复制
发表时间：
2001-04-01
影响因子：
1.5
通讯作者：
Comín, JM
中科院分区：
文献类型：
--
作者：
Fernández, A;Cortés, M;Comín, JM
本研究的目的是分析接受新辅助化疗 (NC) 的乳腺癌患者的闪烁扫描和伽玛探针前哨淋巴结 (SN) 定位的准确性。该研究纳入了 76 名单发乳腺癌患者，并分为两组。第 1 组由 40 名接受 NC 的女性组成，第 2 组由 36 名未接受 NC 的女性组成。所有患者均通过瘤周注射接受 111 MBq (3 mCi) 3 ml 的 Tc-99(m)-纳米胶体。注射后2小时进行前胸和侧胸扫描。第二天（注射后 18-24 小时），患者接受手术，并使用伽马探针定位前哨淋巴结。所有患者均进行了完整的腋窝淋巴结清扫术。组织学分析包括所有病例的苏木精-伊红和10例的免疫组织化学分析。在第 1 组中，SN 位于 36/40 名患者中，34 名患者进行了组织学分析，有 4 名假阴性 (22%)。在第 2 组中，SN 位于 32/36 名患者中，29 名患者进行了组织学分析，有两个假阴性 (9%)。第 1 组和第 2 组的预测阴性值分别为 78% 和 90%。总之，接受过新辅助化疗的乳腺癌患者的前哨淋巴结定位不如未接受过新辅助化疗的患者准确。该手术对于定位前哨淋巴结不够准确，因此不推荐用于这些患者。 （(C) 2001 Lippincott Williams & Wilkins）。
The aim of this study was to analyse the accuracy of scintigraphic and gamma probe sentinel node (SN) localization in breast cancer patients who have been submitted to neoadjuvant chemotherapy (NC). Seventy-six patients with single breast cancer were included in the study, and were classified into two groups. Group 1 consisted of 40 women who had received NC, and Group 2 consisted of 36 women who did not receive NC. All patients received 111 MBq (3 mCi) of Tc-99(m)-nanocolloid in 3 ml, by peritumoural injection. Anterior and lateral thoracic scans were obtained 2 h post-injection. The following day (18-24 h post-injection) the patients underwent surgery and sentinel nodes were localized by using a gamma probe. Complete axillary lymph node dissection was performed in all patients. Histological analysis included haematoxylin-eosin in all cases and immunohistochemistry in 10 cases. In Group 1, SNs were localized in 36/40 patients, histological analysis was performed in 34 and there were four false negatives (22%). In Group 2, SNs were localized in 32/36 patients, histological analysis was performed in 29 and there were two false negatives (9%). Predictive negative values were 78% and 90% in Groups 1 and 2, respectively. In summary, sentinel node localization in breast cancer patients submitted to previous neoadjuvant chemotherapy is less accurate than in patients who do not receive this therapy. The procedure is not sufficiently accurate to localize the sentinel node, thus it cannot be recommended in these patients. ((C) 2001 Lippincott Williams & Wilkins).